So far, published data suggests that a GLP-1 alone can make progress on steatosis in MASH within a 72-week time frame
Green vs
A 2025 analysis found that GLP-1 agonists given for diabetes were associated with a reduced risk of substance use among hundreds of thousands of United States Veterans and a 2024 examination of over 500k patients 4 Qeadan, F., McCunn, A., & Tingey, B
The eureka moment, as Habener puts it, was when they discovered that in the larger precursor protein proglucagon, there was a signal peptide, an intervening peptide, a peptide that was homologous to mammalian glucagon, and then a second GLP-related peptide later revealed to be GLP-1
Lets look at the evidence
The antioxidant completely gets absorbed much more quickly when directly injected into the bloodstream [6] as opposed to when it gets administered orally